Benjamin F. Edwards & Company, Inc. Intellia Therapeutics, Inc. Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 60,913 shares of NTLA stock, worth $741,920. This represents 0.02% of its overall portfolio holdings.
Number of Shares
60,913
Previous 861
6974.68%
Holding current value
$741,920
Previous $24,000
5579.17%
% of portfolio
0.02%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding NTLA
# of Institutions
314Shares Held
91.5MCall Options Held
442KPut Options Held
880K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.3MShares$149 Million2.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.63MShares$117 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$117 Million0.0% of portfolio
-
State Street Corp Boston, MA5.14MShares$62.6 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.95MShares$60.3 Million3.75% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $926M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...